

# Preceptorship Lung Cancer

## INFORMATION

### Preceptorship Lung Cancer

📅 18<sup>th</sup> and 19<sup>th</sup> March 2025

📍 Auditorium Cellex  
C/ Natzaret 115-117  
Barcelona 08035

#### Coordination:

Dra. Enriqueta Felip

#### How to arrive:

🚇 **L3** Vall d'Hebron    🚌 Líneas **19 y 76**

**18<sup>th</sup> and 19<sup>th</sup> March 2025**

Coordination: Dra. Enriqueta Felip

# PRECEPTORSHIP LUNG CANCER

18<sup>th</sup> and 19<sup>th</sup> March 2025

## Day 1 | 18<sup>th</sup> March

- 9.00-9.20 h • **Welcome and presentation.** Dr. Enriqueta Felip
  - 10 min presentation / 10 min discussion
- 9.20-9.50 h • **Molecular alterations NSCLC.** Dr. Augusto Valdivia
  - 20 min presentation / 10 min discussion
- 9.50-10.20 h • **Exon 20 epidemiology.** Dr. Patricia Irazo
  - 20 min presentation / 10 min discussion
- 10.20-10.40 h • **Coffee**
- 10.40-11.00 h • **NGS testing in NSCLC with a focus in EGFR sensitizing and EGFR exon 20 insertion mutations.** Dr. Javier Hernández
  - 20 min presentation
- 11.00-11.30 h • **Joint discussion of NGS reports (molecular tumor board cases).** Dr. Javier Hernández
  - 20 min presentation / 10 min discussion
- 11.30-12.00 h • **Perioperative treatment in patients with EGFR mutations.** Dr. Alex Martínez
  - 20 min presentation / 10 min discussion
- 12.00 - 12:30 h • **Treatment combinations in first line EGFR mutations: Updated results of MARIPOSA / FLAURA.** Dr. Susana Cedrés
  - 20 min presentation / 10 min discussion
- 12:30 - 13:00 h • **Treatment combinations in first line EGFR mutations: Updated results of MARIPOSA / FLAURA (vs osimertinib) in high-risk biological subgroups (ctDNA+, co-mutation of p53) & mechanisms of acquired resistance.** Dr. Núria Pardo
  - 20 min presentation / 10 min discussion
- 13:00 - 13:30 h • **First line amivantamab/Lazertinib: managing toxicity.** Dr. Ilaria Priano. 20 min presentation / 10 min discussion
- 13:30 - 14:00 h • **Discussion of clinical cases presented by the delegates.** All (moderated by Dr. Enriqueta Felip)
- 14:00 - 14:30 h • **Lunch**
- 14:30 - 15:30 h • **Tour (Cellex)** Javier Gonzalo

## Day 2 | 19<sup>th</sup> March

- 9:00 - 9:30 h • **Second line EGFR approaches, including MARIPOSA-2.** Dr. Núria Pardo
  - 20 min presentation / 10 min discussion
- 9:30 - 10:00 h • **Histological SCLC transformation in EGFR-mutant NSCLC.** Dr. Pedro Rocha
  - 20 min presentation / 10 min discussion
- 10:00 - 10:30 h • **Clinical cases discussion.** Dr. Augusto Valdivia
- 10:30 - 11:00 h • **Coffee**
- 11:00 - 11:30 h • **Treatment in patients with EGFR exon 20.** Dr. Susana Cedrés.
  - 20 min presentation / 10 min discussion
- 11:30 - 12:00 h • **New therapies for EGFR exon 20 patients; potential sequences.** Dr. Patricia Irazo
  - 20 min presentation / 10 min discussion
- 12:00 - 12:30 h • **ADC in EGFR mutated patients.** Dr. Oriol Mirallas
  - 20 min presentation / 10 min discussion
- 12:30 - 13:00 h • **New treatment strategies in EGFR uncommon mutations.** Dr. Ilaria Priano
  - 20 min presentation / 10 min discussion
- 13:00 - 13:30 h • **Amivantamab subcutaneous formulation.** Dr. Alex Martínez
  - 20 min presentation / 10 min discussion
- 13:30 - 14:00 h • **Discussion of clinical cases presented by the delegates.** All (moderated by Dr. Enriqueta Felip)
- 14:00 - 14:30 h • **Lunch**
- 14:30 - 15:30 h • **Tour (UITM)** Dr. Oriol Mirallas

